Pharmacodynamic profiling of ceftobiprole for treatment of complicated skin and skin structure infections

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 8, 2009, Pages 3371-3374

  Kimko, Holly ^a   Xu, Xu ^a   Nandy, Partha ^a   Samtani, Mahesh N ^a   Strauss, Richard S ^b   Bagchi, Partha ^a   Noel, Gary J ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTOBIPROLE;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; SKIN INFECTION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CEFTAZIDIME; CEPHALOSPORINS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; SKIN DISEASES, INFECTIOUS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 67749143993     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01653-08     Document Type: Article

References (17)

1. Ambrose, P. G., S. M. Bhavnani, C. M. Rubino, A. Louie, T. Gumbo, A. Forrest, and G. L. Drusano. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44:79-86.
2. Breiman, L., J. Friedman, R. Olshen, and C. Stone. 1998. Classification and regression trees. CRC Press LLC, Boca Raton, FL.
3. Clinical and Laboratory Standards Institute. 2005. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. M7-A6. Clinical and Laboratory Standards Institute, Wayne PA.
4. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial disk susceptibility tests, 15th ed. M2-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Craig, W. A., and D. R. Andes. 2008. In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models. Antimicrob. Agents Chemother. 52:3492-3496.
6. Drusano, G. L., S. L. Preston, C. Fowler, M. Corrado, B. Weisinger, and J. Kahn. 2004. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J. Infect. Dis. 189:1590-1597.
7. Entenza, J. M., P. Hohl, I. Heinze-Krauss, M. P. Glauser, and P. Moreillon. 2002. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob. Agents Chemother. 46:171-177.
8. Forrest, A., D. E. Nix, C. H. Ballow, T. F. Goss, M. C. Birmingham, and J. J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081.
9. Jones, M. E. 2007. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus. Clin. Microbiol. Infect. 13(Suppl. 2):17-24.
10. Kimko, H. H., B. Murthy, X. S. Xu, P. Nandy, R. Strauss, and G. J. Noel. 2009. Population pharmacokinetic analysis of ceftobiprole for the treatment of complicated skin and skin structure infections. Antimicrob. Agents Chemother. 53:1228-1230.
11. Lodise, T. P., Jr., R. Pypstra, J. B. Kahn, B. P. Murthy, H. C. Kimko, K. Bush, G. J. Noel, and G. L. Drusano. 2007. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrob. Agents Chemother. 51:2378-2387.
12. Lodise, T. P., N. Patel, A. Renaud-Mutart, E. Gorodecky, T. R. Fritsche, and R. N. Jones. 2008. Pharmacokinetic and pharmacodynamic profile of ceftobiprole. Diagn. Microbiol. Infect. Dis. 61:96-102.
13. Mouton, J. W., A. Schmitt-Hoffmann, S. Shapiro, N. Nashed, and N. C. Punt. 2004. Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141. Antimicrob. Agents Chemother. 48:1713-1718.
14. Murthy, B., and A. Schmitt-Hoffmann. 2008. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity. Clin. Pharmacokinet. 47:21-33.
15. Noel, G. J., K. Bush, P. Bagchi, J. Ianus, and R. S. Strauss. 2008. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin. Infect. Dis. 46:647-655.
16. Noel, G. J., R. S. Strauss, K. Amsler, M. Heep, R. Pypstra, and J. S. Solomkin. 2008. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by grampositive bacteria. Antimicrob. Agents Chemother. 52:37-44.
17. Preston, S. L., G. L. Drusano, A. L. Berman, C. L. Fowler, A. T. Chow, B. Dornseif, V. Reichl, J. Natarajan, and M. Corrado. 1998. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 279:125-129.